• ELUXA HM EMSI is an ongoing pivotal Phase II global

  2020-07-13

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• WES and validation by Sanger sequencing

  2020-07-13

  

  WES and validation by Sanger sequencing in PNGS-252 revealed an apparent homozygous c.4C>G missense alteration (GenBank: NM_014176.3), resulting in the amino Calcipotriol substitution p.Gln2Glu (Figure 1A). This mutation must be very rare, because this is not listed in the NHLBI Exome Sequencing Pr

• As the angular structure of compound cannot be differentiate

  2020-07-13

  

  As the angular structure of compound cannot be differentiated from the linear structure by H NMR spectroscopy, a NOESY NMR experiment was performed to unambiguously characterize the regioselectivity of the final compound. In the linear compound , a signature correlation between the proton of the t

• The first example of a broadly

  2020-07-13

  

  The first example of a broadly-acting antiviral drug is ribavirin, a nucleoside analogue that was proposed to act directly at the level of the viral polymerase, although an indirect effect via inhibition of the host-cell IMP dehydrogenase and depletion of the GTP pool seems more plausible [9]. Anoth

• Introduction Formate dehydrogenase enzymes FDHs are a

  2020-07-13

  

  Introduction Formate dehydrogenase enzymes (FDHs) are a group of heterogeneous proteins that catalyse the reversible formate () oxidation to carbon dioxide () (Eq. (1)). These enzymes are classified in two families, one gathering the enzymes that hold no redox-active centres and another that includ

• A small subset of compounds composed

  2020-07-13

  

  A small subset of compounds composed the 5-[1,2,4]triazino[5,6-]indole cluster (). This series of compounds was characterised by a central heterocyclic core with an R1 alkyl amine chain, required for potency (. , , and ), with preference for morpholine over piperidine (. ). The scaffold can be subst

• Functional studies suggested the presence of a cysLT recepto

  2020-07-13

  

  Functional studies suggested the presence of a cysLT1 receptor. We observed an LTD4-induced cytosolic calcium response, albeit one that was very weak by most standards. The magnitude of the average response was partially explained by the low percentage of PDK1 inhibitor synthesis showing a very tran

• The classification of CK substrates

  2020-07-13

  

  The classification of CK2 substrates based on active enzyme subunit composition provides a framework for understanding the regulatory function of CK2β subunit. However, few experiments exist that functionally explore such classification [17], [18], [19], [20], [21], [22], [23]; this reflects practic

• Napabucasin The UPR is composed of three different pathways

  2020-07-11

  

  The UPR is composed of three different pathways that fall under the control of three respective ER transmembrane proteins: PERK, IRE1α (inositol-requiring enzyme 1α) and ATF6 (activating transcription factor 6). As a starting signal for the UPR, misfolded proteins induce the release of GRP78 from th

• The methods used for cytokine analysis such

  2020-07-11

  

  The methods used for cytokine analysis, such as ELISA or multiplex systems could also influence the concentrations of cytokines analysed. It is therefore crucial to use the same lot of the multiplex analysis kit to make such a comparison [21]. In our study, we ensured that the analysis was performed

• br Acknowledgments br Introduction Cell cycle arrest or dela

  2020-07-11

  

  Acknowledgments Introduction Cell cycle arrest or delay may occur at 3 major checkpoints, i.e. G1/S, intra-S and G2/M. p53 has a central role in controlling the G1/S checkpoint, and its loss or deactivation, occurring in the majority of cancers, forces cancer cells to rely on the S and G2/M ch

• In order to evaluate the

  2020-07-11

  

  In order to evaluate the in vivo pharmacology associated with EP receptor antagonism, we wished to discover antagonists presenting a higher degree of selectivity over the other prostanoid receptors. We also wanted to increase the brain–blood ratio since it is probable that centrally mediated EP agon

• br Introduction Our understanding of how ligands interact wi

  2020-07-11

  

  Introduction Our understanding of how ligands interact with G protein coupled receptors is evolving, particularly the recognition that some have the ability to preferentially activate a subset of intracellular signalling cascades – so called pathway biased ligands [1]. Additionally, it is now acc

• Although many of the hepatic responses

  2020-07-11

  

  Although many of the hepatic responses observed on the first day of recovery attenuated over the course of the recovery period, minimal-to-mild centrilobular hepatocellular hypertrophy tended to persist. Mean absolute and relative liver weights had returned to control levels after 28 days of recover

• br Analytical improvements Since our review of Oxysterol Met

  2020-07-11

  

  Analytical improvements Since our review of “Oxysterol Metabolomes” in 2011 [7], there have been a number of improvements in analytical methods for the analysis of oxysterols and related compounds. McDonald and colleagues in Dallas have refined their LC-MS methods which are now applicable for ana

16523 records 843/1102 page Previous Next First page 上5页 841842843844845 下5页 Last page